The FDA approved a revision on March 26 to the warnings and precautions sections of labeling for zafirlukast (Accolate, made by AstraZeneca) describing the associated risk of hepatotoxicity.

Cases of life-threatening hepatic failure have been reported to the FDA. Patients should be advised to be alert for signs and symptoms of liver dysfunction such as right upper quadrant abdominal pain, nausea, fatigue, lethargy, pruritus, jaundice, flu-like symptoms, and anorexia. Patients should contact their physician immediately if these occur, the FDA advised.

The FDA approved revisions on March 25 to the precautions and adverse reactions sections of labeling for ciprofloxacin hydrochloride tablets and oral suspension (Cipro, made by Bayer), describing the associated risk of Achilles and other tendon ruptures.

Reports have been received by the FDA of tendon ruptures resulting in prolonged disability or requiring surgical repair in patients receiving ciprofloxacin and other quinolones. The risk may be increased in patients concomitantly receiving corticosteroids, especially in the elderly. The FDA recommends that ciprofloxacin be discontinued if the patient experiences pain, inflammation, or rupture of a tendon.
This is a part of article Cipro - Now FDA Approved! Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

Ciprofloxacin is also associated with the risk of pseudomembranous colitis. Discontinuation resolves most mild cases. Treatment of moderate to severe cases should involve consideration of fluids and electrolyte management, protein supplementation, and treatment with an antibacterial drug clinically effective against C. difficile colitis. Drugs that inhibit peristalsis should be avoided, the FDA advised.

FDA Expands Warning to Include More Bone Cements and Bone Void Fillers

On May 7, the FDA expanded its Oct. 31, 2002, advisory to the healthcare community to include all bone cements (polymethylmethacrylate and calcium phosphate) and bone void fillers that are not specifically cleared and labeled for vertebroplasty or kyphoplasty, warning that there have been serious complications from the use of acrylic bone cements in treating compression fractures of the spine.

The FDA advises physicians to follow the labeling when using bone cement cleared by FDA for vertebroplasty or kyphoplasty. Those considering the use of bone cements and bone void fillers not cleared by FDA for this purpose should be especially attentive to patient selection, treatment techniques, potential complications, and patient monitoring. Physicians should also be aware of the literature in this area, as well as recommendations from professional organizations.
This is a part of article Cipro - FDA Expands Warning. Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

Precautions include use of ethambutol in pediatric patients aged 13 years and younger, and in nursing mothers due to drug excretion in breast milk. It should not be administered within four hours of aluminum hydroxide–containing antacids, which reduce ethambutol’s mean serum concentration and urinary excretion rate.

Atazanavir (Reyataz) Interacts With Phosphodiesterase-5 Inhibitors

On March 16, the FDA approved revisions to the warnings and precautions sections of labeling for atazanavir sulfate capsules (Reyataz, made by Bristol-Myers Squibb), describing a drug interaction with phosphodiesterase-5 (PDE5) inhibitors prescribed for erectile dysfunction.

Ciprofloxacin (Cipro) Associated With Tendon Ruptures, Pseudomembranous Colitis

The FDA warns that concurrent administration of PDE5 inhibitors (sildenafil, tadalafil, or vardenafil) in patients receiving protease inhibitors such as atazanavir sulfate is expected to substantially increase PDE5 inhibitor concentration and may result in PDE5 inhibitor–mediated effects such as hypotension, visual changes, and priapism.

Zafirlukast (Accolate) Associated With Hepatotoxicity
This is a part of article Ciprofloxacin precautions. Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

The U.S. Food and Drug Administration (FDA) has approved revisions to safety labeling for ethambutol hydrochloride, atazanavir sulfate, zafirlukast, ciprofloxacin hydrochloride, and bone cements and bone void fillers.

Ethambutol (Myambutol) Associated with Decreases in Visual Acuity

The FDA approved revisions on March 24 to the contraindications, precautions, and adverse reactions portions of the safety labeling for ethambutol hydrochloride (Myambutol, made by Wyeth).

Ethambutol may produce decreases in visual acuity, including irreversible blindness that may appear to be due to optic neuritis. Symptoms of optic neuropathy include decreased visual acuity, scotoma, color blindness, and/or visual defect. These events have also been reported in the absence of a diagnosis of optic or retrobulbar neuritis.

Ethambutol hydrochloride is contraindicated in patients with optic neuritis unless clinical judgment determines that it may be used. It is also contraindicated in patients who are unable to appreciate and report visual adverse effects or changes in vision, such as young children or unconscious patients.

Other adverse reactions include hypersensitivity, anaphylactic reactions, neutropenia, hypersensitivity syndrome, and pulmonary infiltrates with or without eosinophilia. Ethambutol is also contraindicated in patients who are known to be hypersensitive to this drug.
This is a part of article Safety labeling for ciprofloxacin. Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

A higher risk for peptic ulcer disease was reported in corticosteroid users who were receiving nonsteroidal anti-inflammatory drugs (NSAIDs) concurrently ( Table 1 ). Those receiving NSAIDs and corticosteroids showed a risk for peptic ulcer disease 15 times greater than that of nonusers of either drug.Antihistamines

Elderly persons treated with first-generation histamine cipro H1 receptor antagonists (antihistamines) may be at greater risk of adverse effects involving the CNS, such as sedation or impaired cognitive function.

Diphenhydramine administration in hospitalized patients ??70 years of age was associated with a higher risk of cognitive decline compared with nonexposed patients ( Table 1 ). These findings strongly suggest caution when prescribing this drug to the elderly. Reports by Mann, et al. of sedation with second-generation antihistamines loratadine, cetirizine (Zyrtek®, Pfizer), fexofenadine (Allegra®, sanofi-aventis) and acrivastine (Sempra®, GlaxoSmithKline) were infrequent, but this study did not focus on the elderly. Affrime et al. studied pharmacokinetics and adverse events of desloratadine (Aerius®, Schering) in different age groups and suggested that no dosage adjustment of desloratadine is required in the elderly. Immunobiological Agents

Three immunobiological cipro agents have been approved by the US FDA for the treatment of moderate-to-severe psoriasis: alefacept (Amevive®, Astellas), efalizumab (Raptiva®, Genentech), and etanercept (Enbrel®, Amgen Wyeth). A recent study found alefacept to be well tolerated and effective in elderly, obese, and diabetic patients with moderate-to-severe plaque psoriasis. Accidental injury, headache, and pharyngitis were among the most common adverse events. Infections were primarily colds, with no opportunistic infections being reported. In psoriatic patients ??65 years of age treated with efalizumab, the overall rates of adverse events were comparable to those seen in patients < 65 years of age, although a higher rate of serious adverse events was observed in the older group.

A recent study evaluated the safety profile of etanercept in patients with chronic, moderate-to-severe plaque psoriasis.19 Pooled safety results from the first 12 weeks of treatment suggest that short-term etanercept treatment is generally safe and well tolerated. No overall differences in safety were observed between older and younger patients.
This is a part of article Cipro causes higher risk for peptic ulcer disease? Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

NEW YORK (Reuters Health) Nov 17 - Once-daily use of a new extended release (ER) formulation of ciprofloxacin (Proquin XR, Depomed) is as effective as intermediate-release (IR) ciprofloxacin (CIPRO, Bayer) in treatment of uncomplicated urinary infection in women, according to researchers.

Ciprofloxacin ER “showed efficacy that was clearly at least as good as ciprofloxacin IR twice daily,” investigator Dr. Bret Berner told Reuters Health.

Dr. Berner, of Depomed Inc., Menlo Park, California, and colleagues note in the October issue of Antimicrobial Agents and Chemotherapy that by reducing the release rate of ciprofloxacin, the ER formulation may reduce gastrointestinal side effects and improve patient compliance.

To investigate, the researchers studied 272 women with uncomplicated urinary infection who were randomized to the ER formulation 500 mg daily for three days. A further 257 women received 250 mg of the IR formulation twice daily for three days.

Clinical cure rates at up to 11 days after treatment were 85.7% in the ER group and 86.1% in the IR group. Biological and clinical cure rates outcomes at up to 6 weeks after treatment were similar for both groups and comparable to the earlier findings.

Both treatments were well tolerated but the frequency of nausea in the ER group (0.6%) was significantly lower than that in the IR patients (2.2%). This was also true of diarrhea (0.2% versus 1.2%).

The researchers conclude that the ER formulation is not inferior to the IR variety and leads to significantly fewer adverse gastrointestinal effects.

“Ciprofloxacin ER has such a low incidence of nausea and diarrhea that is the only marketed fluoroquinolone where the label treats these as uncommon adverse events,” Dr. Berner said.
This is a part of article Cipro review, by David Douglas Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

Purpose: The effect of omeprazole on the oral bioavailability and urinary exposure of the Depomed formulation of extended-release(ER) ciprofloxacin was studied.
Methods: A two-way crossover study was conducted in healthy subjects. Subjects received either a single dose of ER ciprofloxacin 1000 mg or a single dose of ER ciprofloxacin 1000 mg following three days of treatment with omeprazole 40 mg. Blood and urine samples were collected over 36 hours, and ciprofloxacin concentrations were determined using high-performance liquid chromatography.
Results: Twenty-seven subjects (16 men, 11 women) received both treatments. The mean maximum concentration, mean area under the plasma-versus-concentration curve, and mean amount of ciprofloxacin excreted in urine were similar between the two treatments and met strict bioequivalence criteria.
Conclusion: Omeprazole did not affect the plasma or urinary pharmacokinetics of an oral ER formulation of ciprofloxacin.Introduction

Ciprofloxacin is a fluoroquinolone antimicrobial agent with a broad spectrum of activity against both gram-negative and gram-positive bacteria.[1,2] One oral extended-release (ER) formulation of ciprofloxacin hydrochloride (Proquin XR, Depomed, Inc.) delivers 90% of a 500-mg dose (of ciprofloxacin) over a six-hour period to the upper-gastrointestinal (GI) tract, where ciprofloxacinis best absorbed.[3] This formulation contains polymeric excipients that cause the tablet to enlarge in the stomach by absorbing water from the gastric fluid. The tablet relies on a combination of size and the physiology of the fed stomach to delay gastric emptying and provide extended release of ciprofloxacin. Omeprazoleis a gastric proton-pump inhibitor that blocks acid production in the stomach, resulting in decreased gastric acidity and potentially altered drug absorption.[4,5] Although the bioavailability of conventional, immediate-release ciprofloxacin is not affected by coadministration with omeprazole,[6] the absorption and systemic availability of ciprofloxacin from another ER formulation (Cipro XR, Bayer) are reduced when the drug is coadministered with omeprazole.[7] Hence, the objective of this study was to determine the effect of omeprazole on the oral bioavailability and urinary excretion of the Depomed formulation of ER ciprofloxacin.
This is a part of article Imipenem-Cilastatin or Ampicillin-Sulbactam or Cipro-Ciprofloxacin. Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

The incidence of A. baumannii bacteremia steadily increased over 10 years from no cases in 1987 to 0.35 cases/1000 patient-days in 1999 (Figure 1). During the same time, susceptibilities remained relatively stable for A. baumannii blood isolates. Both ampicillin-sulbactam and imipenem-cilastatin had minimal decreases from 100% susceptible in 1989-1993 to 99% susceptible in the last 4 years. The organism remained relatively resistant to penicillins, cephalosporins, and ciprofloxacin (Figure 2).

Clinical outcome assessments illustrated no difference between groups. There was no difference in time of white blood cell count or temperature return to normal; clinical response at day 2, day 7, or end of treatment; or antibiotic-related ICU and total length of stay (Table 2). The cost of treatment of A. baumannii bacteremia is high regardless of antimicrobial agent, with median antibiotic costs for ampicillin-sulbactam equal to $500 (range $50-1220) compared with $1500 (range $220-7520) for imipenem-cilastatin (p=0.0002). Median cost of hospital-ization of an ampicillin-sulbactam-treated patient was $30,000 (range $9600-177,000) versus $43,200 (range $13,200-178,000) for an imipenem-cilastatin-treated patient.

Forty-four percent of imipenem-cilastatin-treated patients and 37% of ampicillin-sulbactam-treated patients received combination therapy with an aminoglycoside. Analysis of these variables led to several interesting findings. Patients who received imipenem-cilastatin with another agent had a significantly longer total length of stay than those given monotherapy (median 57 vs 33 days, p=0.03), whereas there were no significant differences in clinical outcomes between ampicillin-sulbactam combination and monotherapy. Compared with patients who received ampicillin-sulbactam monotherapy, those who received imipenem-cilastatin combination therapy had longer ICU stays (median 36 vs 17 days, p=0.04), total length of stay (median 57 vs 27 days, p=0.006), and higher hospital and antibiotic costs. Antibiotic-related length of stay was significantly shorter (median 8 vs 13 days, p=0.008) for patients who received ampicillin-sulbactam plus an aminoglycoside compared with imipenem-cilastatin alone.
This is a part of article Cipro - investigation results. Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

Risk chemical reaction and chemoprevention of prostate metastatic tumor are important objectives. The 5a-reductase inhibitor propecia may interfere with the territorial dominion or move of prostate genus Cancer. Currently approved for use in BPH, finasteride reduces the transition of testosterone to dihydrotestosterone, a more potent androgen, and decreases prostate size [see 10:XIII Benign Prostatic Hyperplasia — omitted]. Although a large, double-blind, placebo-controlled legal proceeding (the Prostate Metastatic tumor Prevention Trial) demonstrated a 24.4% diminution in election prostate metastatic tumor with finasteride, discipline patients who developed prostate house while taking finasteride were more likely to have higher-grade mortal.80 This puzzling judgment has stymied the use of finasteride as a incumbrance official - purchase propecia cheap.
This is a part of article Prevention of Prostate Cancer. Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

Patients at high risk for spontaneous rupture of tendons include those on steroid therapy or long-term dialysis; those with gout, rheumatoid arthritis, or advanced age; and those who have had renal transplantation. Whether fluoroquinolones should be used in patients with a history of tendon problems or those with risk factors for development of tendon rupture depends on the seriousness of the infection and the alternatives available. High-risk patients require close surveillance.

Typically, fluoroquinolone-associated tendon symptoms occur within the first few weeks after therapy in started. Fluoroquinolone treatment should be discontinued at the first sign of tendon inflammation so as to reduce the risk of subsequent rupture. If further investigation is warranted, magnetic resonance imaging (MRI) is useful in distinguishing between Achilles tendonitis and partial tendon rupture.

In addition to prompt discontinuation of fluoroquinolone therapy, management of tendonitis consists of placing the tendons at rest, which may include the use of a cane, crutches, splinting, or casting.Posted 11/20/2001.
This is a part of article Ciprofloxacin therapy. Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

Anti-Infective Agents.

Infections are a common problem among the elderly, and anti-infective agents are frequently prescribed to them. In elderly patients, ADRs, as well as drug interactions, should be considered when selecting an anti-infective regimen. Common drug interactions with anti-infective agents involve macrolide antibacterials and fluoroquinolones.

Erythromycin and troleandomycin are strong inhibitors of the cytochrome P450 enzyme CYP3A4, and may therefore be responsible for toxicity of coadministered drugs by decreasing their clearance ( Table 1 ). Example substrates of CYP3A4 include benzodiazepines, calcium channel antagonists, immunosuppressive agents (e.g., cyclosporin, tacrolimus ), and anticoagulants. Elderly patients receiving macrolides should be monitored for adverse events resulting from drug interactions.

Fluoroquinolones are antibacterials that are frequently used in infections affecting the elderly. One of the most important drug interactions of fluoroquinolones is the ability of ciprofloxacin (Cipro, Bayer) and enoxacin to inhibit the metabolism of theophylline by CYP1A2, resulting in theophylline accumulation and toxicity. Seizures may occur at therapeutic theophylline levels as a result of its additive effects on the central nervous system (CNS).Corticosteroids

Corticosteroids have adverse effects on many organ systems, ranging from those that are not necessarily serious (e.g., Cushingoid appearance), to those that are life-threatening (e.g., serious infections). Some of these adverse effects may be aggravated in the elderly. Patients receiving prednisolone 5-40mg/day for at least 1 year had a partial loss of explicit memory, and elderly patients may be more susceptible to memory impairment with less protracted treatment ( Table 1 ). The risk of developing diabetes mellitus more than doubles in elderly patients who are newly initiated on oral corticosteroid therapy.
This is a part of article Cipro and Adverse Drug Reactions in the Elderly Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

E. coli was the predominant organism (44%), which was primarily treated with nitrofurantoin (92% susceptibility) and ciprofloxacin. While susceptibility to ciprofloxacin was lower in both types of healthcare settings, it was significantly lower in the long-term compared with the acute care facilities, at 43% and 70%, retrospectively.

“We’re now seeing a lot of resistance to empiric antibiotics that we usually use for UTIs, Kwan said. ‘We can’t really initiate empiric antibiotic treatment with confidence that the organisms will actually be susceptible to them.”

“There is a growing problem within long-term care,” she noted. “We have frequent transfer of residential patients between long-term care and acute care, but it’s more of a concern when these long-term care patients transfer to an acute care setting. We worry that some of the resistance is transferring over there as well,” Kwan explained.

Clinicians should be vigilant about when to treat, and wait for cultures to come back before initiating treatment, she continued. If treatment is needed immediately, “an antibiotic such as cephalosporin would probably be more effective than the broad-spectrum antibiotics that we’ve been using.”

Her group recommends that clinicians adhere to the criteria set by the Society of Healthcare and Epidemiology of America (SHEA) for initiating antibiotics for UTIs in long-term care settings.

Kwan also pointed out that “it’s important for clinicians to be aware of local susceptibility data for their site and their particular region, because it can vary.”

Susceptibility to Cipro has gone down over the last few years as well, Kwan said. “We’re not only seeing it in long-term care and in UTIs, but in acute care where there is more widespread use of oral and intravenous quinolones.”
This is a part of article Predominant organism treated with Cipro Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

Figure 2. (click image to zoom) Percentage of antimicrobials susceptible to A. baumannii, 1989-1998. For imipenem-cilastatin, data are from August 1990-1998. Ami = amikacin; A-S = ampicillin-sulbactam; Ceftaz = ceftazidime; Cipro = ciprofloxacin; I-C = imipenem-sulbactam; Pip = piperacillin.

Presumed eradication occurred in 97% of patients receiving ampicillin-sulbactam and 100% of those treated with imipenem-cilastatin. One patient treated with ampicillin-sulbactam did not have repeat cultures and died before hospital discharge. Concomitant organisms included a variety of gram-negative and gram-positive organisms, as well as Candida sp (Figure 3). The respiratory tract was the site most frequently concomitantly infected with A. baumannii (ampicillin-sulbactam 47%, imipenem-cilastatin 72%). Other positive culture sites were wounds, urine, catheter tips, and eyes.

Figure 3. (click image to zoom) Frequency/patient of concomitant organisms.

Imipenem-cilastatin dosages ranged from 2-4 g/day intravenously or the renal-dosed equivalent. Fifty percent of patients received 500 mg intravenously every 6 hours, 44% received 1 g intravenously every 6 hours, and 1 patient (6%) received 500 mg intravenously every 8 hours. Ampicillin-sulbactam dosages ranged from 1 g ampicillin-0.5 g sulbactam intravenously every 6 hours (20%) to 2 g ampicillin-1 g sulbactam intravenously every 6 hours (80%), or its renal-dosed equivalent.
This is a part of article Cipro - acinetobacter baumannii blood isolate Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

SAN FRANCISCO (Reuters Health) Sept 28 - Long-term care facilities with high rates of urinary tract infections (UTI) caused by quinolone-resistant Escherichia coli may represent a “reservoir of risk” for patients in acute care facilities, researchers from Vancouver, British Columbia reported Wednesday at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy.

Lead investigator Leanne Kwan, clinical pharmacist at St. Paul’s Hospital, and associates noticed an overuse of ciprofloxacin within the facilities of a large integrated healthcare organization. They also noticed an increase in resistant UTIs, which prompted a retrospective study to identify patterns of transmission, the antibiotic selection process and possible resistance patterns in these populations.

Evaluation of the records for a 1-year period for about 800 patients in acute and long-term care facilities in the Providence Health Care system revealed positive urine cultures in 130 patients, Kwan told Reuters Health.
This is a part of article Cipro side effects, by Deborah Mitchell Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

from Pediatric Pharmacotherapy
Drug Interactions and Dosing Recommendations

Drug Interactions Ciprofloxacin, like the other quinolones, interacts with many other medications and nutrients (Tables 1 and 2). A large percentage of these interactions are the result of interference with cytochrome P450 1A2 function.[4]

Ciprofloxacin should not be given simultaneously with enteral feedings. Patients may take ciprofloxacin with food, but should be instructed to avoid taking dairy products such as milk and yogurt, iron, or zinc supplements at the same time as a ciprofloxacin dose.

Dosing Recommendations Ciprofloxacin (Cipro; Bayer) is currently available as an injection in 200mg/20 ml and 400 mg/40 ml vials, as tablets in 100, 250, 500, and 750 mg strengths, and as a oral liquid suspension 250 mg/5ml and 500 mg/5ml. Based on the studies reviewed, the usual dosage regimen for pediatric patients is 10 mg/kg given every 8 hours or 15 mg/kg given every 12 hours.
This is a part of article Ciprofloxacin Use in Children: A Review of Recent Findings Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog